Skip to content

Elixirgen Therapeutics

3 viewers · 30d

Total raised

$8.2M

3 filings since 2025 · latest SAFE filed

Cumulative raised
LAST ROUND
SAFE · $4.0M
ROUNDS
3
INVESTORS
2
FOUNDED
N/A
HQ
Baltimore, MD
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
3

AI overview

Updated

Elixirgen Therapeutics, Inc. is a cutting-edge biotechnology firm dedicated to the development of innovative RNA therapeutics aimed at addressing a broad spectrum of medical challenges. The company is committed to providing treatment solutions for rare diseases, cancer, and aging-related conditions that currently have limited therapeutic options.

What sets it apart

Elixirgen Therapeutics stands out for its focus on next-generation RNA therapeutics, particularly in targeting rare diseases and aging-associated conditions, backed by strategic partnerships and advanced technology platforms.

Funding history

3 rounds
SAFE+2Oct 30, 2025
Form D
+$4.0M$8.2M total
SAFE+2Mar 31, 2025
Form D
+$3.6M$4.2M total
SAFE+2Jan 30, 2025
Form D
+$600K$600K total

Products

1 tracked

mRNA Therapeutic Platform

RNA Therapeutics

Elixirgen Therapeutics' mRNA platform is at the forefront of developing innovative therapeutics designed to address rare and complex diseases. This platform enables the creation of potent treatments that can potentially modulate genetic expressions to treat conditions effectively.

  • Next-generation RNA technology
  • Focus on genetic and aging-related disorders
  • Advanced therapeutic delivery capabilities